Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites

Abstract

Cytoreductive surgery with immediate HIPEC and HIPEC with dCRS, determined by vital sign stability, may lead to similar outcomes in OC patients with malignant ascites.

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

“…According to our previous experience 3 rounds of HIPEC was used to treat abdominal tumors in order to get good outcomes (22)(23)(24)(25), consequently, BHPC was also conducted for 3 rounds in the present study. Nevertheless, for our self-developed device-based BHPC, the chemotherapeutic types of drugs and dosages involved, the treatment time and temperature are still being explored.…”

“…During hyperthermic intraperitoneal chemotherapy, widely employed in the treatment of ovarian cancer and malignant ascites with satisfactory outcomes (22)(23)(24)(25), the temperature probes sensed the temperature of the perfusion liquid or within the abdominal cavity instead of the tumor tissues directly. However, this did not hamper hyperthermia in the cancer tissues.…”

“…We developed a 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system', which allows precise automatic control of the temperature and perfusion rate of the drug solution. This system includes an automatic cooling function and adaptive fuzzy control technology for precise control of the perfusion temperature and rate, and thus, control of the local temperature in the bladder cavity of NMIBC patients (22)(23)(24)(25). To effectively kill the residual cancer cells within the bladder as well as to kill the cancer cells dropped from the bladder cavity and adhered to the bladder wall, BHPC using this device was performed immediately after the TUR of bladder tumors instead of weeks later.…”

“…In addition, the pharmacokinetics of chemotherapeutic agents during thermochemotherapy is also not well understood. Over the past 6 years, we performed continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites using a novel 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system' which can precisely maintain the temperature and perfusion rate of the drug solution, with satisfactory outcomes (22)(23)(24)(25). However, conductive BHPC for bladder cancer has been rarely reported.…”

Hyperthermic Intraperitoneal Perfusion Chemotherapy and Cytoreductive Surgery for Controlling Malignant Ascites From Ovarian Cancer

“…1,2 With increasing amounts of ascites, patients generally report progressive symptoms of abdominal swelling, pain, nausea and dyspnea. Indeed, discomfort and decreased quality of life (QOL) associated with symptomatic malignant ascites often exceed that of the cancer itself, resulting in detrimental physiological and psychological states that lead to a poor prognosis.…”